The next Saxenda? Companies race to occupy GLP-1 RA market
By | translator Alice Kang
22.02.14 06:00:43
가나다라
0
Saxenda becomes the sole lead with tis approval in the obesity treatment market… supported by its safety and long-term use data
Novo Nordisk prepares launch of its long-acting new formulation… increases convenience with a once-weekly dose from the previous once daily dose
Lilly expands into the obesity market with tirzepatide… domestic companies also in the run to develop new products
GLP-1 class drugs are taking over the obesity treatment market. With ‘Saxenda’ in the lead, pharmaceutical companies in Korea and abroad are racing to catch up with Novo Nordisk, while the company is working to bring another improved GLP-1 analogue into the market.
According to industry sources on the 14th, pharmaceutical companies in Korea and abroad are busy developing obesity treatments using GLP-1 analogues. Lilly is spurring up the development of its product in the market currently occupied by Novo Nordisk, with Hanmi Pharmaceutical and Humedix in Korea also conducting research.
◆Novo Nordisk spurs up development of an improved product based on Saxenda’s success
(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)